After proving the diagnosis of breast carcinoma, the remaining tissue in the biopsy is needed to assess further biomarkers, such as estrogen/progesterone receptors and HER2/neu expression, which guide clinical management and treatment decisions [15]. The gene discussed is ERBB2; the disease is breast carcinoma.